Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Eukaryotic Gene Expression
Fator do impacto: 2.156 FI de cinco anos: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Imprimir: 1045-4403
ISSN On-line: 2162-6502

Volume 30, 2020 Volume 29, 2019 Volume 28, 2018 Volume 27, 2017 Volume 26, 2016 Volume 25, 2015 Volume 24, 2014 Volume 23, 2013 Volume 22, 2012 Volume 21, 2011 Volume 20, 2010 Volume 19, 2009 Volume 18, 2008 Volume 17, 2007 Volume 16, 2006 Volume 15, 2005 Volume 14, 2004 Volume 13, 2003 Volume 12, 2002 Volume 11, 2001 Volume 10, 2000 Volume 9, 1999 Volume 8, 1998 Volume 7, 1997 Volume 6, 1996 Volume 5, 1995 Volume 4, 1994

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.v13.i24.170
10 pages

Prostaglandin E—A Powerful Anabolic Agent for Generalized or Site-Specific Bone Formation

Yannis Vrotsos
Department of Periodontology, University of Athens School of Dentistry, Athens, Greece
Scott C. Miller
Division of Radiobiology, University of Utah, Salt Lake City, UT; and 3Department of Cell Biology, University of Massachusetts Medical School, Worcester, MA
Sandy C. Marks, Jr.
Department of Cell Biology, University of Massachusetts Medical Center, Worcester 01655, USA


Prostaglandins are locally secreted, rapidly metabolized, biologically active fatty acids first identified in the prostate. The role of prostaglandins in the inflammatory response has been widely studied. However, some prostaglandins, particularly those of the E series (PGEs), can suppress inflammation, making it difficult to understand the local events and their sequence. This bimodal potential of the PGEs has been poorly understood in skeletal biology, causing the initial report of PGEs as mediators of bone resorption to persist for more than two decades, despite ample evidence to the contrary. This resulted in part from the power of any initial report to overrule subsequent conflicting views and in part on the exclusive reliance on in vitro data to explain in vivo phenomena. Over a decade ago, the potential of PGEs as authentic anabolic skeletal agents was demonstrated convincingly in vivo by both systemic and local delivery. The potential clinical applications of the PGEs in skeletal biology have not yet been developed. Our purpose is to review the reasons for the delayed discovery of the true skeletal effects of the PGEs and to describe applications for this technology. With the development of appropriate delivery systems, one can anticipate widespread clinical applications of the PGEs to accelerate skeletal repair, and to treat skeletal pathologies and trauma.

Articles with similar content:

Targeting of EPH Receptor Tyrosine Kinases for Anticancer Therapy
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 2
Martin Lackmann, Eva Nievergall, Thomas Saunders
Critical Aspects in Rationale Design of Fluorouracil-Based Adjuvant Therapies for the Management of Colon Cancer
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 2
Vivek Ranjan Sinha, Honey
The Human Knee Meniscus: A Review with Special Focus on the Collagen Meniscal Implant
Journal of Long-Term Effects of Medical Implants, Vol.21, 2011, issue 4
Robert (Trey) Hansen, Eli Bryk, Gene Choi, Vincent J. Vigorita
The Use of Scaffolds in Cartilage Regeneration
Critical Reviews™ in Eukaryotic Gene Expression, Vol.28, 2018, issue 4
Rasime Kalkan, Chidi Wilson Nwekwo, Terin Adali
Implant-Associated Infections: An Overview
Journal of Long-Term Effects of Medical Implants, Vol.16, 2006, issue 1
Robert G. Sawyer, T. L. Hedrick, J. D. Adams